Inhibitors of gastric secretion: current progress.
Several new compounds have become available recently which are potent inhibitors of gastric secretion. The therapeutic potential of these inhibitors in the peptic ulcer diathesis is reviewed and it is concluded that the histamine H2-receptor antagonists show most promise at present. The prostaglandins and gastro-intestinal polypeptides are of considerable physiological interest but are unlikely to have clinical importance in the immediate future.
D000818:Animals; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005750:Gastric Juice / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects; D005768:Gastrointestinal Hormones / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008785:Metiamide / Q000009:adverse effects; D010437:Peptic Ulcer / Q000188:drug therapy*; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011454:Prostaglandins A / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology; D012633:Secretin / Q000494:pharmacology; D013004:Somatostatin / Q000494:pharmacology; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy
D005768:Gastrointestinal Hormones; D006146:Guanidines; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D011448:Prostaglandin Antagonists; D011454:Prostaglandins A; D011458:Prostaglandins E; D012633:Secretin; D008785:Metiamide; D013004:Somatostatin; D004815:Epidermal Growth Factor